Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SHR-1918 in mixed hyperlipidemia
CTR20253886Phase 3Active
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1918 in combined dyslipidaemia, sponsored by Beijing Shengdi Pharmaceutical. Started Jan 2026; status: active.
02
Drugs
SHR-1918
03
Conditions
combined dyslipidaemia
Beyond the preview
Go deeper on CTR20253886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253886.